A randomized controlled trial, that is currently in pre-publication, found that a patented complex of Boswellia serrata and Aegle marmelos (Bengal quince fruit extract) called AlvioLife supported respiratory and immune health in healthy subjects.
PLT Health Solutions (Morristown, NJ) has announced the results of a randomized controlled trial, that is currently in pre-publication, which found that a patented complex of Boswellia serrata and Aegle marmelos (Bengal quince fruit extract) called AlvioLife supported respiratory and immune health in healthy subjects. AlvioLife is manufactured by PLT innovation partner Laila Nutraceuticals. In the study, subjects who reported themselves as having air pollution sensitivity took either 200 mg per day of AlvioLife or a matchin placebo for six weeks. Results showed that subjects taking AlvioLife saw statistically significant improvements from baseline, compared to placebo, in lung function (16%), lung capacity (30%), and aerobic exercise capacity (7%). Subjects also reported reductions in upper respiratory tract symptoms as measured by the Wisconsin Upper Respiratory Symptom Scale.
“It’s easy to forget how many aspects of our lives are dependent on respiratory health – from overall health to emotional well-being to physical performance. And factors like environmental pollution can challenge optimal respiratory health,” said Seth Flowerman, president and CEO of PLT Health Solutions, in a press release. “AlvioLife can function as a standalone ingredient to support respiratory function for people who have respiratory sensitivities or live in higher pollution areas, as well as a component in immune health formulations – since the issue of respiratory health is so vital to the immune health equation. For companies looking to differentiate and enhance their immune health formulations, AlvioLife offers some unique benefits.”
According to PLT Health, the combination works via a mechanism of action that helps balance inflammatory response, and that the synergistic blend of botanicals possesses a stronger 5-lipoxygenase (5-LOX) inhibition activity than either constituent alone. The 5-LOX enzyme, says PLT Health, has been shown in literature to influence the onset and progression of airway inflammation.
This new study builds on a previous study1 from 2018 found that supplementation with AlvioLife by subjects with bronchial asthma supported asthma symptoms and inflammatory biomarkers. In the study, 36 subjects took 200 mg per day of AlvioLife or a matching placebo for 56 days. Results showed that supplementation with AlvioLife significantly improved emotional function and asthma symptoms scores within 14 days, compared to placebo, and significantly increased serum IFN‐γ and reduced IL‐4, compared with placebo.
“This new study – conducted on healthy subjects – brings the unique potential of AlvioLife into focus. The new clinical study points to the importance of respiratory health in all phases of our lives. Once again, we demonstrated improved lung function, but we can now see how this also translates into improvements in lung capacity, aerobic exercise capacity and a reduction in upper respiratory tract symptoms,” said Jennifer Murphy, director of innovation and clinical development for PLT. “The measurements of the well-being index suggest that people are indeed happier when they breathe easier,” she said. “For all these reasons, we are seeing interest in AlvioLife as a complementary ingredient in the fast-growing immune health category.”